EIP
ELDN icon

Ellis Investment Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Ellis Investment Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.4K Hold
10,000
– – 0.01% 285
2026
Q1 		$30.8K Buy
+10,000
New +$23.6K 0.01% 268

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Ellis Investment Partners's ELDN Position: Q2 2026 in Review

Ellis Investment Partners held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 10,000 shares worth $39.4K. The position accounts for 0.01% of the portfolio, ranked #285.

Ellis Investment Partners first reported a position in ELDN in Q1 2026 and has held it in 2 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Ellis Investment Partners held 10,000 shares of Eledon Pharmaceuticals worth $39.4K as of Q2 2026.
  • Ellis Investment Partners left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
  • Eledon Pharmaceuticals made up 0.01% of Ellis Investment Partners's portfolio in Q2 2026, its #285 holding.
  • Ellis Investment Partners first reported a position in Eledon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Ellis Investment Partners's 13F filing for Q2 2026, filed 5 Aug 2026.